ResMed Inc. (RMD) CFO Sells $106,237.50 in Stock
ResMed Inc. (NYSE:RMD) CFO Brett Sandercock sold 1,250 shares of ResMed stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $84.99, for a total value of $106,237.50. Following the transaction, the chief financial officer now owns 78,322 shares in the company, valued at approximately $6,656,586.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Brett Sandercock also recently made the following trade(s):
- On Friday, December 1st, Brett Sandercock sold 1,250 shares of ResMed stock. The stock was sold at an average price of $85.36, for a total value of $106,700.00.
- On Wednesday, November 1st, Brett Sandercock sold 1,250 shares of ResMed stock. The stock was sold at an average price of $84.50, for a total value of $105,625.00.
ResMed Inc. (NYSE:RMD) traded up $0.89 during trading on Thursday, hitting $86.42. The stock had a trading volume of 481,300 shares, compared to its average volume of 404,850. ResMed Inc. has a fifty-two week low of $61.63 and a fifty-two week high of $87.81. The company has a debt-to-equity ratio of 0.50, a current ratio of 4.72 and a quick ratio of 3.86. The stock has a market cap of $12,137.04, a P/E ratio of 34.99, a P/E/G ratio of 1.88 and a beta of 0.79.
The business also recently declared a quarterly dividend, which was paid on Thursday, December 14th. Investors of record on Thursday, November 9th were given a $0.35 dividend. This represents a $1.40 annualized dividend and a yield of 1.62%. The ex-dividend date was Wednesday, November 8th. ResMed’s dividend payout ratio (DPR) is presently 56.68%.
A number of hedge funds have recently modified their holdings of RMD. Cubist Systematic Strategies LLC acquired a new position in ResMed during the 3rd quarter worth approximately $113,000. YorkBridge Wealth Partners LLC increased its position in ResMed by 4.9% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 1,476 shares of the medical equipment provider’s stock worth $115,000 after purchasing an additional 69 shares during the period. Toronto Dominion Bank increased its position in ResMed by 12.8% during the 2nd quarter. Toronto Dominion Bank now owns 1,740 shares of the medical equipment provider’s stock worth $135,000 after purchasing an additional 197 shares during the period. BB&T Investment Services Inc. acquired a new position in ResMed during the 2nd quarter worth approximately $214,000. Finally, Visionary Asset Management Inc. acquired a new position in ResMed during the 3rd quarter worth approximately $214,000. Hedge funds and other institutional investors own 61.85% of the company’s stock.
Several research firms have issued reports on RMD. BMO Capital Markets raised their target price on ResMed to $82.00 and gave the stock a “market perform” rating in a research note on Tuesday, December 12th. Zacks Investment Research cut ResMed from a “hold” rating to a “sell” rating in a research note on Tuesday, December 26th. JPMorgan Chase & Co. boosted their target price on ResMed from $72.00 to $73.00 and gave the stock an “overweight” rating in a research note on Monday, October 30th. Needham & Company LLC reissued a “sell” rating on shares of ResMed in a research note on Friday, September 8th. Finally, Barclays lifted their price target on ResMed from $68.00 to $70.00 and gave the stock an “underweight” rating in a report on Friday, October 27th. Five equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $68.71.
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.